Lachowiez, C. A., Zeidner, J. F., Othman, J., Kaempf, A., Yun, S., Heiblig, M., Heuser, M., Shahswar, R., Marroquin, R. M., Cannova, J. M., Zucenka, A., Marvin-Peek, J., Senapati, J., Abaza, Y., Swaroop, A., Zacheo, I., Monaco, F., Belhabri, A., Tauveron-Jalenques, U., Tavernier, E., Carré, M., Requena, G. A., Cook, R. J., Traer, E., Saultz, J. N., O'Nions, J., Basheer, F., Laurie, J., Handa, S., Stein, E. M., Baer, M. R., Olin, R., Blum, W., Schiller, G., Lin, T., Curran, E., Yocum, A., Madarang, E., Daver, N., Kadia, T. M., Marconi, G., Madanat, Y., Dillon, R., DiNardo, C. D., Swords, R., Ossa, J. E. A., Watts, J., Loghavi, S., Pollyea, D. A., Bernard, E. (2026). Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01801